louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04329936: Epidemiological Study on Mental Health of Migrant Population in the Retention Center of Geispolsheim.
Official title: Epidemiological Study on Mental Health of Migrant Population in the Retention Center of Geispolsheim
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mental Health of Migrant Population
Keywords: Mental health
Psychiatric diseases
Migration
Retention center
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2020-04-01
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The migrant population in the retention center of Geispolsheim is male migrants residing in France without authorization. Their retention is decided by the prefecture of Bas-Rhin and Haut-Rhin. The retention happens after custody or at the end of a term of imprisonment.

Brief summary: In 2019, the lack of studies about mental health of the detained population at retention centers in France is pointed out by the report of Controller-General for Places of Deprivation of Liberty. The aim of this study is to contribute to this relatively untouched field by describing which psychiatric pathologies are encountered in this population who went through migration and retention. Having a clearer picture of the situation can help to provide a more adapted psychiatric care in retention centers.

The results are expected to show a higher rate of psychiatric disease than in the general population including addiction to substance, anxiety disorder and post-traumatic stress disorder (PTSD).


Eligibility criteria: Inclusion Criteria:

* Any male person in the first week of detention at CRA Geispolsheim who gave their non-opposition to participation in the study.
* Information and consent protocol signed

Exclusion Criteria:

* Refuse to participate to the study

Primary outcomes:
measure: Mini International Neuropsychiatric Interview validated and translated in the language used by the interviewed person.
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Les Hôpitaux Universitaires de Strasbourg
Study officials:
References:
Clinical trial NCT03460249: Office Blood Pressure Measurement With an Automated Device
Official title: Office Blood Pressure Measurement With an Automated Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Pressure
Lead sponsor: Mercy Health Ohio
Sponsor class: OTHER
First posted: 2018-03-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators plan to determine if the sequence of blood pressure measurements from the sitting position to the table and vice versa has an impact on the measurements.

Detailed description: The investigators plan to measure blood pressure (BP) in 30 consecutive individuals presenting to the St. Elizabeth Boardman Family Health Center. The sample will include patients presenting for their scheduled appointment. Following informed consent (see attached informed consent form), the participants will be randomly assigned to one of two groups. In group A, the sequence of BP measurements will be table position (TP) followed by recommended chair position (RCP) and then, after a 30-minutes rest, the BP will be measured again in the reverse sequence, RCP then TP. In group B, the sequence will begin with BP measurements in the RCP then TP, followed by 30-minutes rest and then measurements will be repeated in the reverse order. The assignment of participants to groups A and B will be random. The BP will be measured twice in each of the positions described above, according the the accepted standard technique, using a digital blood pressure monitor, the OMRON HEM-907 XL.

Eligibility criteria: Inclusion Criteria:

* Patients presenting to the Family Medicine Center age between 18 and 80

Exclusion Criteria:

* Decline to participate for any reason
* Experiencing acute pain or febrile illness
* Pregnant
* Inability to get on the examination table
* Atrial fibrillation, arrhythmia or tachycardia

Primary outcomes:
measure: Percentage of participants whose blood pressures differ with chair to table versus table to chair positioning
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Youngstown
country: United States
facility: Mercy Health Youngstown
state: Ohio
Study officials:
References:
Clinical trial NCT01191736: Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice
Official title: Comparison of the Effectiveness of Ultra-Brief and Brief Hands-Only CPR Video Training With and Without Psychomotor Skill Practice for Lay Responders: a Controlled Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiac Arrest
Keywords: hands only
CPR
resuscitation
cardiac arrest
Education of general public regarding resuscitation methods
Lead sponsor: Valleywise Health
Sponsor class: OTHER
Collaborators: name: American Heart Association
name: University of Arizona
First posted: 2010-08-31
Enrollment: 336
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Bystander CPR improves survival from Out of Hospital Cardiac Arrest. This study examines the efficacy of ultra-brief video training for Hands-Only CPR. Subjects were randomized to one of four training conditions, then assessed for CPR skills retention.

Detailed description: Bystander CPR improves survival from Out of Hospital Cardiac Arrest. This study is the first of its kind to examine the efficacy of ultra-brief video training for Hands-Only CPR without the use of a manikin. The results will inform future efforts to mass train citizens in CPR. Subjects were randomized to one of four training conditions, then assessed for CPR skills retention. The four groups were 1) no training; 2) ultra-brief training video (90 seconds); 3) short training video (5 minutes) with no practice; and 4) short training video with hands-on practice. The subjects were then evaluated for CPR skills retention. One half of the subjects were evaluated on the training day, and the other half were evaluated two months later.

Eligibility criteria: Inclusion Criteria:

* Members of a local area church

Exclusion Criteria:

* Less than 18 years old
* formal CPR training or certification within last 2 years
* Lacks fluency in English
* Works as a health care provider

Primary outcomes:
measure: Median Compression Depth (mm)
timeFrame: 60 minutes after intervention or two months after intervention
Secondary outcomes:
measure: The Proportion of Subjects Who Assessed the Responsiveness of the Victim (Manikin) as Judged by Expert Raters
timeFrame: 60 minutes after intervention and two months after intervention
Other outcomes:
Locations:
Study officials:
affiliation: Valleywise Health
name: Bentley J Bobrow, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bobrow BJ, Vadeboncoeur TF, Spaite DW, Potts J, Denninghoff K, Chikani V, Brazil PR, Ramsey B, Abella BS. The effectiveness of ultrabrief and brief educational videos for training lay responders in hands-only cardiopulmonary resuscitation: implications for the future of citizen cardiopulmonary resuscitation training. Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):220-6. doi: 10.1161/CIRCOUTCOMES.110.959353. Epub 2011 Mar 8.
Clinical trial NCT01839136: Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial
Official title: Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Infertility
Keywords: Assisted Reproductive Techniques
Health Services Accessibility
Ovulation Induction
Embryo Transfer
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2013-04-24
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: The cost for the treatment of infertility are limiting for the health care access, particularly if we consider that the success rate per cycle is approximately 35%. Alternative regimens for controlled ovarian stimulation (COS)have been described in the medical literature, that lead to a lower cost, fewer injections and less risk of adverse events, particularly ovarian hyperstimulation syndrome. Furthermore, some services report excellent results with less manipulation as possible, which reduces the cost of laboratory of human and ethically be considered less complicated once fertilization occurs in the uterus and not in vitro.

Objectives: The main objective is to compare the reproductive outcomes between intrauterine transfer of gametes (TG) and embryos (TE), the secondary objective is to estimate the average number of eggs that are raised when using an EOC reduced cost.

Methods: This study will be conducted in the area of Human Reproduction, Department of Gynecology and Obstetrics Hospital of the FMRP-USP. We will conduct an open controlled study with random allocation of the participants in a 1:1 ratio, and we plan to include 100 participants. All participants will undergo an EOC reduced cost. We will compare the chance of the treatment (TE or TG) result in a live birth and clinical pregnancy per woman allocated and to estimate the number of oocytes retrieved considering all participants.


Eligibility criteria: Inclusion Criteria:

* Women undergoing ART requiring COS, oocyte retrieval and embryo transfer at the fertility clinic of the university Hospital of the Medical School of Ribeirao Preto, University of Sao Paulo, Brazil.
* Age = 18-40 years
* BMI = 18-30 Kg/m²
* Antral follicle count (AFC) ≥ 5
* Semen concentration and progressive motility above the percentile 2.5 of the fertile men (Cooper et al. 2010): sperm concentration \> 9X 10⁶/mL, and progressive motility \> 28%.

Exclusion Criteria:

* None

Primary outcomes:
measure: Live birth
timeFrame: 9 months
Secondary outcomes:
measure: Clinical pregnancy
timeFrame: 2 months
measure: Number of oocytes retrieved
timeFrame: 1 month
Other outcomes:
Locations:
city: Ribeirao Preto
country: Brazil
facility: Setor de Reproducao Humana do HC-FMRP-USP
state: Sao Paulo
Study officials:
References:
Clinical trial NCT06907836: Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine
Official title: Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiac Amyloidosis
Keywords: Cardiac Amyloidosis
Internal medicine
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2025-04-02
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sujet majeur (≥18 ans) avec un diagnostic d'amylose à TTR

Brief summary: In 2024, the prevalence of TTR cardiac amyloidosis is difficult to determine precisely. Indeed, the disease has long been underdiagnosed due to a lack of effective treatment and non-invasive diagnostic methods. The prevalence of ATTRwt is estimated at 155 to 191 cases per million person-years, with an incidence of 36 cases per million person-years. Both incidence and prevalence increase with age.

The most common presentation of TTR cardiac amyloidosis is heart failure with preserved ventricular ejection fraction (LVEF).

The natural history of TTR cardiac amyloidosis is progression to restrictive heart disease with all the complications described above.

The median time between diagnosis and the first cardiac symptoms was 39 months. Currently, the median survival in France is approximately 3.5 years, but survival appears to be improving, with a mortality rate of 73.5% at 30 months between 2002 and 2006, compared to 15% at 60 months between 2017 and 2022.

The number of patients diagnosed with TTR cardiac amyloidosis appears to be increasing. The overwhelming majority of available data concerns patients treated in cardiology. However, the issue of TTR cardiac amyloidosis concerns all specialists caring for patients with heart failure, particularly in internal medicine due to the high number of admissions from emergency departments, with a significant proportion of patients suffering from cardiac decompensation.


Eligibility criteria: Inclusion Criteria:

* Sujet majeur (≥18 ans)
* Diagnostic d'amylose à TTR suite à une hospitalisation en médecine interne aux HUS entre 01/01/2013 au 31/12/2023.

Exclusion Criteria:

* Subject (and/or their legal representative, if applicable) who has expressed their opposition to the reuse of their data for scientific research purposes.
* Type of amyloidosis other than ATTR after review of the medical record (immunological assessment, imaging assessment, expert report).

Primary outcomes:
measure: Describe the number of cases of transthyretin (TTR) cardiac amyloidosis referred to internal medicine between 2013 and 2023.
timeFrame: Up to 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine Interne - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT05233449: NoL Index Response to Stimulation in Anesthetized Children
Official title: Nociception Level Index (NoL) Variation After Standardized Stimulation Under General Anesthesia in Children
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Anesthesia
Keywords: General anesthesia
Nociception
Monitoring
Nociception level
NoL
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2022-02-10
Enrollment: 30
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: In order to avoid the bias related to the order of the stimuli, the order of application of the stimuli will be randomized according to a Latin square of order 3.
Primary purpose: DIAGNOSTIC

Brief summary: The Nociception Level (NoL) is an index obtained via a non-invasive monitor, that is currently used to assess nociception in anesthetized adults. The NoL index varies from 0 to 100. It increases in response to nociceptive stimuli. The objective of this study was to investigate if the NoL index also indicates the level of nociception in anesthetized children. In children anesthetized according to standard practice, before surgical incision, three 5-seconds stimulations will be performed with different intensities (10, 30 and 60 milliamps). The order of the stimulations intensities will be randomized. The hypothesis of study is that the intensity of stimulation will influence the magnitude of NoL-index increase in response to the stimulation.


Eligibility criteria: Inclusion Criteria:

* Age 5-12 years
* Elective surgery under general anesthesia
* Written informed consent

Exclusion Criteria:

* Cardiac surgery
* Opioid intake \< 24 hours before surgery
* Cardiac arrhythmia
* Pace maker
* Pheochromocytoma
* Anti-arrhythmic medication
* Anticholinergic medication
* Raynaud syndrome
* Digital anomaly (malformative, traumatic)

Primary outcomes:
measure: NoL variation = [(Maximal NoL value in the 5 minutes following the stimulation) - (NoL before stimulation)] / [NoL before stimulation]
timeFrame: 5 minutes after stimulation
Secondary outcomes:
measure: Systolic Blood Pressure (SBP) variation
timeFrame: 5 minutes after stimulation
measure: Analgesia Nociception Index (ANI) variation
timeFrame: 5 minutes after stimulation
Other outcomes:
Locations:
city: Lille
country: France
facility: Hopital Roger Salengro, CHU Lille
city: Paris
country: France
facility: Hu Est Parisien Site Trousseau Aphp
Study officials:
affiliation: University Hospital, Lille
name: Nada Sabourdin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04101149: Genetic Causes of Familial Hypercholesterolemia
Official title: Genetiska Orsaker Till familjär Hyperkolesterolemi- Mekanism, Prognos Och Individanpassad Behandling
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Familial Hypercholesterolemia
Lead sponsor: Region Örebro County
Sponsor class: OTHER
First posted: 2019-09-24
Enrollment: 150
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients with suspected FH referred to the cardiac clinic at Orebro University hospital and their first grade relatives.

Brief summary: Familial hypercholesterolemia (FH) is a common disease. The genetic background to FH is not yet fully understood. In the present prospective cohort study we aim to study the association between different clinical characteristics, gene mutations and prognosis.

Detailed description: In this prospective observational cohort study of patients with high clinical suspicion of familial hypercholesterolemia (FH) we aim to study the association between different clinical characteristics, gene mutations and prognosis.

The included patients will undergo physical examination and extended blood sampling. DNA will be extracted and used for both whole genome sequencing and investigation of both known- , unknown- and suspected mutations associated with FH.

The patients will be followed in for 15 years in the Swedish patients registry and the Swedish cause of death registry.

Eligibility criteria: Inclusion Criteria:

1. Age 8 years or older.
2. Clinical suspicion of FH
3. Dutch Lipid Clinic Network Score of at least four or a first grade relative with a genetic deviation that may be associated with FH.

Exclusion Criteria:

1) Age below 8 years.

Primary outcomes:
measure: Prevalence of mutations.
timeFrame: 2 years
Secondary outcomes:
measure: Prognosis, composite endpoint.
timeFrame: 10 years
measure: Prognosis, individual endpoint.
timeFrame: 10 years
Other outcomes:
Locations:
city: Örebro
country: Sweden
facility: Örebro University hospital
Study officials:
affiliation: Örebro University, Sweden
name: Anna M Nordenskjöld, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01895049: Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Transplantation
Cytomegalovirus
Keywords: Tacrolimus
Everolimus
Cytomegalovirus
Thymoglobulin
Deceased donors
Expanded criteria
Lead sponsor: Hospital do Rim e Hipertensão
Sponsor class: OTHER
Collaborators: name: Novartis
name: Sanofi
First posted: 2013-07-10
Enrollment: 171
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The disparity between supply and demand for organs has stimulated the development of strategies to increase the availability of kidney grafts. Such strategy involves the use of kidneys with expanded donor criteria (EDC). This is a study initiated by the investigator, open, prospective, randomized, single center designed to compare the safety and efficacy of two immunosuppressive regimens based on thymoglobulin, tacrolimus and everolimus versus thymoglobulin, tacrolimus and mycophenolate sodium in renal transplant recipients with donor criteria expanded.


Eligibility criteria: Inclusion Criteria:

* Adults (\> 18 years) candidates to renal transplant with expanded criteria deceased donors;
* Low risk of acute rejection, defined as first kidney transplant recipients and Panel Reactive Antibody (PRA) \<50%.
* Signature of the informed consent form (ICF)

Exclusion Criteria:

* Patients receiving immunosuppressive therapy before transplantation;
* Patients who have received an investigational drug within last 30 days;
* Patients with a known contraindication to the administration of an anti-thymocyte globulin;
* Patients with a positive test for human immunodeficiency virus (HIV);
* Patients who had cancer (except non-melanoma skin cancer) within last two years;
* Pregnant women, breastfeeding women, and women of childbearing potential unwilling to use condoms or oral contraceptives will be excluded;
* Patients with any Panel Reactive Antibody (PRA) equal to or higher than 50%, class I or class II, will also be excluded;
* Patients with positive test for parasites (protozoa and helminths).

Primary outcomes:
measure: Incidence of CMV disease
timeFrame: 1 year
Secondary outcomes:
measure: incidence of treatment failure
timeFrame: 1 year
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Hospital do Rim e Hipertensao
Study officials:
References:
citation: Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proenca H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor. Transpl Int. 2019 Nov;32(11):1127-1143. doi: 10.1111/tri.13478. Epub 2019 Aug 27.